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Abstract
The heterogeneous nature of multiple sclerosis (MS) and the unavailability of treatments addressing its intricate network and
reversing the disease state is yet an area that needs to be elucidated. Liraglutide, a glucagon-like peptide-1 analogue, recently
exhibited intriguing potential neuroprotective effects. The currents study investigated its potential effect against mouse model
of MS and the possible underlying mechanisms. Demyelination was induced in C57Bl/6 mice by cuprizone (400 mg/kg/day
p.o.) for 5 weeks. Animals received either liraglutide (25 nmol/kg/day i.p.) or dorsomorphin, an AMPK inhibitor, (2.5 mg/
Kg i.p.) 30 min before the liraglutide dose, for 4 weeks (starting from the second week). Liraglutide improved the behavioral
profile in cuprizone-treated mice. Furthermore, it induced the re-myelination process through stimulating oligodendrocyte
progenitor cells differentiation via Olig2 transcription activation, reflected by increased myelin basic protein and myelinated
nerve fiber percentage. Liraglutide elevated the protein content of p-AMPK and SIRT1, in addition to the autophagy proteins
Beclin-1 and LC3B. Liraglutide halted cellular damage as manifested by reduced HMGB1 protein and consequently TLR-4
downregulation, coupled with a decrease in NF-κB. Liraglutide also suppressed NLRP3 transcription. Dorsomorphin preadministration indicated a possible interplay between AMPK/SIRT1 and NLRP3 inflammasome activation as it partially
reversed liraglutide’s effects. Immunohistochemical examination of I ba+ microglia emphasized these findings. In conclusion,
liraglutide exerts neuroprotection against cuprizone-induced demyelination via anti-inflammatory, autophagic flux activation,
NLRP3 inflammasome suppression, and anti-apoptotic mechanisms, possibly mediated, at least in part, via AMPK/SIRT1,
autophagy, TLR-4/ NF-κB/NLRP3 signaling.
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Graphical abstract

The potential mechanistic insight of Lira in alleviating Cup-induced neurotoxicity via: (1) AMPK/SIRT1 pathways activation resulting in the stimulation of brain autophagy flux (confirmed by lowering Beclin-1 and LC3-B protein expression).
(2) Inhibition of NLRP3 inflammasome activation, as evidenced by reduced HMGB1, TLR-4, NF-κB and NLRP3 protein
expression, alongside diminishing the activation of its downstream cascade as reflected by reduced levels of caspase-1 and
IL-1β protein expression. (3) A possible modulating interplay between the previously mentioned two pathways.
Keywords AMPK/SIRT1 · Autophagy · Dorsomorphin · Liraglutide · Multiple sclerosis · NLRP3 inflammasome

Introduction
Multiple sclerosis (MS) is a neurodegenerative disease of
the central nervous system (CNS) featured by chronic cardinal progressive immune-mediated neuro-inflammatory
events that lead to neuronal demyelination, loss of myelinproducing oligodendrocytes (OLGs), and eventually nerve
fibers destruction (Khan et al. 2014). Nowadays, MS is
manifested as the most prevalent cause of non-traumatic
progressive neurological disabilities in youth—about
2.3 million affected individuals globally (Browne et al.
2014)—impairing movement, sensory functions and cognition (Omotoso et al. 2018; Zidan et al. 2018). The currently available treatments mostly target the manipulation
of immune response although improving oligodendrocyte
progenitor cells (OPCs) differentiation into mature myelin-producing OLGs, which is a crucial step in reversing
the degeneration by re-myelination, is an emerging yet
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elusive therapeutic strategy (Kremer et al. 2016; Plemel
et al. 2017).
Sirtuin 1 (SIRT1), a histone deacetylase-Sirtuin family
member, is a key modulator of the inflammatory responses.
SIRT1 suppresses immunoinflammation via nuclear
factor-κB (NF-κB) expression attenuation (Matsushita
et al. 2013). The AMP-activated protein kinase (AMPK)
is a critical regulator of mitochondrial energy homeostasis (Largani et al. 2019). AMPK exerts anti-inflammatory
activity in a SIRT1-dependent manner (Peixoto et al. 2017).
Additionally, AMPK and SIRT1 mutually modulate each
other showing synergistic activity (Lan et al. 2008). Previous
studies elucidated that the AMPK/SIRT1 pathway mediates
neuroprotection, partially, through inducing the autophagy
machinery hence suppressing cellular damage and apoptotic
processes especially via mitochondrial-specific autophagy
(mitophagy) (Jin et al. 2014; Yan et al. 2017; Kruppa et al.
2018). In this context, cuprizone (Cup), a copper chelator,
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has been reported to exert a reproducible neurotoxicity that
results from perpetuating mitochondrial energy homeostasis
(Zatta et al. 2005) and copper-dependent enzymes inhibition
(Messori et al. 2007). Accordingly, it generates a drastic
metabolic oxidative stress leading to apoptosis of OLGs,
microgliosis and astrogliosis (Hillis et al. 2016).
Nucleotide-binding and oligomerization domain-like
receptors-pyrin domain-containing protein 3 (NLRP3)
inflammasome is damage motifs sensitive cytosolic protein complex that is expressed by phagocytes including
macrophages and dendritic cells (Guo et al. 2015). They
are essential part of the protective innate immune response,
on the other hand, their over-activation is a key factor in
multiple neurodegenerative diseases including MS through
copious inflammatory cytokines production including
interleukin-1β (IL-1β) and IL-18 (Swanson et al. 2019).
IL-1β, a profound mature inflammatory cytokine processed
by inflammasomes in microglia, has a pivotal role in cell
death and the disturbance of blood–brain barrier integrity
(Schrijver et al. 2003; Wang et al. 2014). Noteworthy, targeting NLRP3 inflammasome is an emerging strategy in
manipulating MS (Shao et al. 2018).
Data suggest that a cross-talk between AMPK/SIRT1
and NLRP3 inflammasome pathways may occur through
NF-κB modulation and/or mitigating mitochondrial damage
via mitochondrial reactive oxygen species (mtROS) (Yan
et al. 2017; Zou et al. 2018). Furthermore, previous studies revealed that AMPK activation may have a suppressive
activity on Toll-like receptor-4 (TLR-4) expression, subsequently attenuating NLRP3 activation (Soraya et al. 2012,
2014). The previous findings cast light on targeting both
AMPK/SIRT1 and NLRP3 as an outstanding strategy in the
treatment of MS.
Liraglutide (Lira) is a glucagon-like peptide-1 (GLP-1)
analogue that is characterized by a high amino acid sequence
similarity, 97%, with the human GLP-1. It’s approved for
type-2 diabetes mellitus, as a once-daily antidiabetic agent,
without hypoglycemic side effects (Jacobsen et al. 2016).
Its kinetic properties allow it to pass the blood–brain barrier and subsequently activate the widely distributed GLP-1
receptors (GLP-1R) in the brain (Hunter and Hölscher 2012;
McGovern et al. 2012; Cork et al. 2015). Previous studies
have reported some neuroprotective effects of Lira in animal
models of Alzheimer’s disease (Hansen et al. 2016), Parkinson’s disease (Badawi et al. 2017), cognitive impairment
(Liu et al. 2020), cerebral ischemia (Briyal et al. 2014), and
diabetic peripheral neuropathy (Moustafa et al. 2018a, b).
The Cup model is a widely used mouse model imitating demyelination–re-myelination events in different brain
regions (Klein et al. 2018). Therefore, we hypothesized that
Lira has a possible neuroprotective effect against the Cup
demyelinating model and a potential to induce re-myelination, suggesting its dual benefit for MS patients with diabetic
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co-morbidity. Herein, we focused on AMPK/SIRT1 and
NLRP3 inflammasome pathways as well as the subsequent
defective autophagy, inflammation, and apoptosis.

Materials and methods
Animals
This in-vivo study utilized male C57Bl/6 mice (8–10 weeks
old, 20–25 g in weight). Mice were kept in the animal facility of the Faculty of Pharmacy, The British University in
Egypt (BUE) (Cairo, Egypt) 1 week before the start of the
experiment. They were maintained under standard conditions of five mice per cage and 12/12 h light/dark cycle (with
lights on at 6 am) at a constant temperature (23 ± 2 °C). Animals were allowed free access to standard chow diet and
water ad libitum. The experiment followed the guidelines
of the animal facility and the experimental protocol was
approved by the ethical committees at the British University in Egypt (Approval No. EX-1901, September 2019) and
the faculty of pharmacy, Cairo University (Approval No.
PT-2421, April 2019).

Drugs
Cuprizone (Bis (cyclohexanone) Oxaldihydrazone) and dorsomorphin (Dorso) (6-[4-(2-Piperidin-1-ylethoxy) phenyl]3-pyridin-4-ylpyrazolo [1, 5-a]pyrimidine) were purchased
from Sigma–Aldrich Co. USA. Liraglutide was acquired
from Novo Nordisk pharmaceutical company, USA. Any
other chemical used was of analytical grade with the highest purity.

Demyelination induction
Cuprizone suspension was prepared by mixing the powder
with 0.1% methylcellulose (MC) and vortexed to obtain a
homogenous suspension. Animals received Cup (400 mg/kg/
day p.o) using oral gavage throughout a period of 5 weeks to
induce acute demyelination (Zhen et al. 2017).

Experimental design and study time scale
Animals were assigned randomly into four groups
(n = 15); thereafter they were subjected to the following
treatments: (i) Normal control group: received 0.1% MC
(10 ml/kg p.o.) (Zhen et al. 2017). (ii) Positive control
group: received daily oral Cup suspension as described
before. (iii) Liraglutide-treated group: received Cup + Lira
(25 nmol/kg/day i.p.) for 4 weeks. (iv) Liraglutide and
Dorso-treated group: received Cup + Lira + Dorso (2.5 mg/
kg i.p.) 30 min right before Lira injection and it was
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dissolved with normal saline (Lee et al. 2019). A power
analysis of power = 0.8 and α = 0.05 was performed to
determine the group size with an effect size used previously by Elbaz et al. (2018).
Treatment with Lira and Dorso was introduced at the
second week of the regimen and continued for 4 weeks.
This design is illustrated in Fig. 1. Liraglutide dose has
been selected as it was reported to have a neuroprotective
effect in previous animal studies (Hunter and Hölscher
2012; McClean and Hölscher 2014).
Behavioral assessments were conducted 24 h after the
last dose injection. Eventually, animals were euthanized
by decapitation under light anesthesia; afterwards, the
whole-brain tissues were rapidly excised and weighed.
Within each group, tissues were randomly divided into
two subsets: one for histopathological examination and
immunohistochemical analysis (n = 3) and the other for the
investigation of biochemical parameters (n = 12).

Behavioral studies
Animals’ locomotor and motor coordination activities
were assessed using open field test (OFT), rotarod and grip
strength tests. Worthy of note, behavioral tests were performed with a minimum of 30 min rest interval in between
and during animals’ light cycle to avoid any discrepancies
due to circadian changes.

R. A. Ammar et al.

Open field test
Animals were allocated centrally in a square white wooden
box arena, 40 × 40 × 25 cm, illuminated by white dim light,
and allowed free uninterrupted movement. The testing apparatus was cleaned using 70% ethanol between subjects to
eliminate any bias by left odors. The locomotor activity of
each mouse was recorded within a noise-attenuated room
for 3 min period, tracked and analyzed via ANY-maze software (version 6.0, Stoelting Co., Wood Dale, USA). The test
arena was virtually divided into (4 × 4 cm) 16 equal squares
and locomotor parameters including distance traveled, mean
speed, mobility time, ambulation frequency (line crossings)
and rearing frequency for each animal were assessed (Walsh
and Cummins 1976; Keller et al. 2018).
Rotarod test
Assessment of motor coordination was performed using a
standard rotarod apparatus (rotating at 25 rpm around a 3-cm
diameter rod). At first, mice were allowed to acclimatize
to maintain their posture on the rotating rod through three
5 min-training sessions on three consecutive days. After
assessing the locomotor activity via open field test, animals
were placed on the rotating rod and the time each mouse
took before falling off the rod was determined as the latency
period with a maximum cut-off value of 300 s (Jones and
Roberts 2011; Gilli et al. 2016).

Fig. 1  Experimental time scale of Lira and Dorso in Cup-induced demyelination mouse model
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String test
String test has been used as a method to assess grip strength
implicating the neuromuscular function (Brooks and Dunnett
2009; Takeshita et al. 2017). Mice were allowed to hang on
a horizontal steel wire (35 cm in length and 2 mm in diameter) by their forelimbs. The latency period through which
each mouse was hanging on the wire before losing grip was
recorded (Cut-off value 3 min).

Sample preparation
Brain tissues were collected, rinsed with ice-cold phosphate
buffered saline (PBS) to remove any blood residues, and dissected into two hemispheres through the midline. Then, tissues
were immersed in liquid nitrogen to snap freeze and stored
at − 80 °C till the analysis of the biochemical parameters.
Brain hemispheres were homogenized with radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris–HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1%
SDS) and protease and phosphatase inhibitor cocktail (Pierce,
ThermoFisher Scientific, USA) for protein extraction, and the
homogenate was then constantly agitated for 1 h at 4 °C. The
mixture was centrifuged for 30 min at 12,000 rpm at 4 °C and
the supernatant was aspirated and stored at − 80 °C. Total
protein content was quantified using bicinchoninic acid protein
quantification kit (ThermoFisher Scientific, USA, Catalogue
No. 23225). Protein extracts were used for western blot analysis and enzyme-linked immunosorbent assay (ELISA).

Biochemical analysis
Determination of brain p‑AMPK, HMGB1, NF‑κB, NLRP3,
Caspase‑1, and IL‑1β via enzyme‑linked immunosorbent
assay
Mouse p-AMPK (Thr 172) (Catalogue No. MBS7230575,
My BioSource, USA), NF-κB (P65) (Catalogue No.
MBS775083, My BioSource, USA), high mobility group
box protein-1 (HMGB1, catalogue No. CSB-E08224r, CUSABIO Technology LLC, China,), NLRP3 (Catalogue No.
LS-F39627, LSBio, USA), caspase-1 (Catalogue No. NBP275014, Novus Biologicals, USA) and IL-1β (Catalogue No.
MLB00C, R&D systems, USA) protein expression were
determined and quantified using ELISA kits according to
the manufacture’s protocol.
Western blot analysis of SIRT1, TLR‑4, MBP, Olig2,
and autophagy biomarkers (Beclin‑1 and LC3B) protein
expression
Equal amounts of protein samples (30 μg) were allowed to
separate on 4–20% Precast polyacrylamide (SDS–PAGE)
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gels (ThermoFisher Scientific, USA). Thereafter, into a
nitrocellulose membranes (Optitran®, Whatman), the separated proteins were transferred. Following the transfer, the
nitrocellulose membranes were washed with 1X Tris Buffered Saline (1X TBS) and then blocked with 3% milk in 1X
TBS for 1 h at room temperature. Subsequently, membranes
were incubated overnight at 4 °C with the recommended
dilutions of primary antibodies against SIRT1 (Catalogue
No. MA5-32912), myelin basic protein (MBP, Catalogue
No. MA5-27818), Olig2 (Catalogue No. P21954), Beclin-1
(Catalogue No. PA5-20171), and LC-3B (Catalogue No.
PA5-85081) from ThermoFisher Scientific (USA) as well as
TLR-4 (Catalogue No. 14358S) and GAPDH (Catalogue No.
2118) from Cell Signaling (USA). After washing with 0.1%
tween in TBS, membranes were incubated with the corresponding peroxidase-labeled secondary antibodies at room
temperature for 1 h. Finally, the protein-antibody complexes
were visualized using enhanced chemiluminescent horseradish peroxidase (HRP) substrate (SuperSignal West Pico
plus Chemiluminescent, ThermoFisher Scientific, USA) by
scanning the membrane for chemiluminescent bands at the
expected molecular weight of the protein via C-DIGIT® blot
Scanner (Li-Cor Biosciences, USA). The protein bands density was finally analyzed using Image studio digits software
version 5.0 (Li-Cor Biosciences, USA) and the results were
then normalized with GAPDH protein expression.

Histopathological examination
Using 10% neutral buffered formalin, whole-brain tissues
were fixed for 72 h. Afterwards, brain tissue samples were
processed in serial dilutions of ethanol (100–95%), cleared
in xylene and embedded into Paraplast tissue embedding
media. Five-micron thick sagittal brain sections were cut
from the paraffin tissue blocks by rotatory microtome. Then,
the processed tissue sections were deparaffinized and stained
with Harris Hematoxylin and Eosin (H&E) stain for general
tissue examination, in addition to Luxol fast blue (LFB) for
evaluation of myelinated nerve fibers percentage in corpus callosum regions from different samples of all groups.
Samples fixation and processing were applied according to
(Culling 2013). The histopathological examination was performed by an experienced investigator who was blinded to
samples’ identity to eliminate any bias in the results.

Immunohistochemical assessment of Iba+ microglial
cells
Unstained deparaffinized 5 μm-thick brain tissue sections were cut and processed with 3% hydrogen peroxide
for 20 min, washed by PBS, and incubated with ionized
calcium-binding adaptor molecule 1 (Iba-1) primary antibody (Abcam, USA, Catalogue No. ab108539) overnight
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at 4 °C after 1:100 dilution. HRP performed complex and
3,3̀-diaminobenzidine (DAB) were used for detection of
Iba+ microglia according to manufacturer’s instructions
(Dako, Denmark). After washing by PBS, tissue slides were
counter-stained with hematoxylin for microscopic analysis.
Micrographs were captured by Full HD microscopic camera processed by Leica application module (Leica Microsystems GmbH, Wetzlar, Germany). The immunohistochemical
examination was performed by an experienced investigator
who was blinded to samples’ identity to eliminate any bias
in the results.

Statistical analysis
A Shapiro–Wilk test was performed to check for the normality of distribution of all parametric data sets. Data
that passed the requirements for parametric criteria were
then analyzed by one-way analysis of variance (one-way
ANOVA) followed by Tukey–Kramer posts hoc statistical
tests and presented as mean ± standard deviation (S.D.).
However, data sets that did not meet the parametric requirements were analyzed using non-parametric Kruskal–Wallis
ANOVA followed by Dunn’s post hoc statistical tests and
presented as median and range. Data were analyzed and
visualized using GraphPad Prism software (Version 9, San
Diego, CA, USA). A cut-off value of less than 0.05 was
accepted as a statistically significant P value level. Additionally, to confirm that, sample sizes had the sufficient power
to detect a statistically significant effect, Mead’s “Resource
Equation” was applied (Mead et al. 2012).

Results
Lira ameliorated cuprizone‑induced behavioral
abnormalities
Behavioral tests demonstrated that Cup administration
resulted in a significant deterioration in the locomotor activity and motor coordination parameters compared to the normal control group as displayed in Fig. 2a & b. Treatment
with Lira significantly reversed the behavioral changes as it
depicted an increase in the total distance traveled by mice,
mean speed, time being mobile, and rearing frequency (OFT
test) reaching levels approximately 4-, 3-, 3- and 4-fold,
respectively, greater than those in the cuprizone-treated
group. Interestingly, Lira increased the retention time of
animals on the rotating rod before falling (rotarod test) and
the latency period the mice took hanging on the steel wire
(string test) reaching approximately 5- and 8-fold the cuprizone-treated group values, respectively, compared to the
Cup-treated group. Meanwhile, combining Lira with Dorso
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caused worsening in the behavioral parameters compared to
the Lira-treated group.

Lira reversed cuprizone‑induced brain weight
alterations
As shown in Fig. 3a, a significant reduction of 14.7% in
brain weight was induced by Cup administration in comparison to normal control group. Whereas, Lira significantly
increased the brain weight by 15% compared to the Cup
group and almost maintained the brain weight compared to
normal group. Combining Lira with Dorso decreased brain
weight by 3% compared to Lira-treated group.

Lira improved cuprizone‑induced alteration
in the brain myelination status.
The percent of myelinated nerve fibers in different corpus
callosum fields as well as MBP and Olig2 relative protein
expression were measured to assess the effect of Lira administration on C57Bl/6 mice brain myelination status.
As shown in Fig. 4, Cup administration significantly
evoked a defect in the myelination status of mice brain tissues, which is evidenced by the significant decrease in the
percentage of myelinated nerve fibers in different corpus callosum brain sections by 46.7%, as depicted by LFB-staining.
In contrast, Lira treatment significantly increased the intensity of LFB-staining by 35% and consequently increased
the percentage of myelinated nerve fibers in comparison
to the Cup group. Worthy of note, Dorso co-administration
reduced the percentage of myelinated nerve fibers in comparison to Lira-treated group.
Fig. 3a and b also shows that Lira administration significantly improved the myelination markers in C57Bl/6 mice
brains as manifested by the increased levels of MBP and
Olig2 relative protein expression reaching approximately
1.5- and 2-fold, respectively, compared to the Cup group.
Interestingly, by combining Lira + Dorso, MBP protein
expression significantly decreased, while it showed almost
the same level of Olig2 in comparison to the Lira-treated
group.

Lira activated AMPK/SIRT1 pathway
in cuprizone‑induced neurotoxicity
Fig. 5a and b presents the experimental data where Cup
administration showed a marked reduction in p-AMPK and
SIRT1 levels by 53.6 and 68.8%, respectively, compared to
normal control group. Interestingly, Lira almost normalized
p-AMPK and SIRT1, when compared with normal control
group. In addition, it caused a significant augmentation in
both proteins expression reaching approximately 2- and
3-fold, respectively, when compared to the Cup-treated
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Fig. 2  Effect of Lira on Cup-induced alterations in locomotion &
motor ability in C57Bl/6 mice through OFT, rotarod and string test.
a Table of the behavioural analysis results. Each value represents the
mean ± S.D. except for the rearing frequency, values represent the
median and range of 12 mice in the open field arena. b Represents
track plots showing the position of the centre of the mice in OFT test.

Statistical significance between groups was detected using one-way
ANOVA followed by Tukey–Kramer post hoc tests except for rearing frequency, which was analyzed using Kruskal–Wallis ANOVA
followed by Dunn’s post hoc statistical tests. aSignificantly different
from Normal group, bSignificantly different from Cup group, cSignificantly different from Cup + Lira group at P < 0.05

group. On the other hand, combining Lira + Dorso was able
to partially block Lira-induced stimulation of p-AMPK/
SIRT1 proteins as confirmed by the significant reduction of
p-AMPK and SIRT1 by 28.9 and 51.1%, respectively, when
compared to Lira-treated rats.

protein expression by 1.5- and 4.4-fold compared to Liratreated group.

Lira augmented autophagic flux
in cuprizone‑induced demyelination
To investigate the effect of Lira administration on C57Bl/6
mice brain autophagy, Beclin-1 and LC3B proteins expression was measured. As presented in Fig. 5c & d, Cup administration inhibited the autophagy pathway as manifested by
the reduction of Beclin-1 and LC3B-B (II/I ratio) proteins
expression by nearly 2- and 3.3-fold, respectively, compared
to normal control group. Lira treatment augmented the brain
autophagy process as evidenced by the significant increase
in the protein expression of both Beclin-1 and LC3B (II/I
ratio) reaching levels approximately 3- and 6-fold, respectively, when compared to the Cup group. Meanwhile, coadministration of Dorso with Lira gave rise to a defect in
brain autophagy, a finding that was confirmed by a concomitant decrease in both Beclin-1 and LC3B-B (II/I ratio)

Lira inhibited NLRP3 inflammasome
activation and OLGs apoptotic biomarkers
in cuprizone‑induced neurotoxicity
Cuprizone intoxication significantly evoked the protein expression of HMBG1 and upregulation of TLR4, hence increased the expression of NF-κB (Fig. 6).
Consequently, the NLRP3 downstream cascade proteins
were highly expressed. Also, Cup augmented the apoptotic flux as evidenced by increasing the expression of
caspase-1 and IL-1β by 2- and 1.5-fold, respectively,
compared to normal mice. On the other hand, Lira was
capable of curtaining the inflammation induced by Cup
ingestion via NLRP3 inflammasome. In the Lira-treated
group, HMGB1, TLR-4, NF-κB and NLRP3 proteins
expression were decreased by 1.4-, 4.1-, 3- and 1.3-fold,
respectively, compared to the Cup-treated group. Furthermore, Lira exhibited a suppression of the apoptotic process as depicted by the significant decrease in apoptotic
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Fig. 3  Effect of Lira on Cup-induced alterations in brain weight and
brain myelination biomarkers of C57Bl/6 mice. Vertical bars represent the mean ± S.D. of 12 mice for a brain weight, as well as six

mice for b MBP and c Olig2 relative protein expression. Values are
statistically significant at P < 0.05 using one-way ANOVA followed
by Tukey–Kramer post hoc tests

biomarkers caspase-1 and IL-1β by 3- and 1.6-fold,
respectively, less than that observed in Cup-treated group.

Lira ameliorated cuprizone‑induced microgliosis

Histopathologic evaluation of different brain
coronal sections
According to Fig. 7, corpus callosum sections of normal
control mice showed normal histological structures with
normal myelinated nerve fibers and minimal abnormal
glial cells infiltrates. The administration of Cup elicited
focal regions of reactive astroglial and microglial cells
infiltrates. Moreover, it showed moderate demyelination,
vacuolization and axonal damage showing higher interaxonal spaces all-over corpus callosum. Lira-treated corpus callosum sections presented a significant reduction
in glial cells infiltrates with mild focal axonal demyelination. However, most of the fields showed intact and more
organized morphological features. On the other hand, sections from Lira + Dorso-treated mice demonstrated almost
the same histological records as Cup-treated sections.
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To investigate the relative activation of microglial cells in
brain corpus callosum sections, Anti-Iba-1 immunohistochemical staining was performed. According to Fig. 8, Cuptreated sections showed an elevated Iba-1 positive staining
reaching approximately 8-fold compared to normal control.
Interestingly, treatment with Lira was able to reduce the
Iba+ stained microglial cells by 73.7% compared to the Cuptreated group. However, combing Lira + Dorso caused an
increase in the number of Iba-1 positively stained microglia
reaching 3-fold compared to the Lira-only treated group.

Discussion
The current study divulged, for the first time, new mechanistic insights of the ameliorative effects of Lira on Cupinduced demyelination through the modulation of AMPK/
SIRT1, autophagy flux, and NLRP3 inflammasome neuroinflammatory pathways, and its potential effect to trigger
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Fig. 4  Representative images showing the effect of Lira on Cupinduced deterioration in myelinated nerve fibers percentage. LFBstained brain corpus callosum coronal sections (magnification, × 50)
of: a Normal control group, b Cup-, c Lira-, d Lira + Dorso-treated
groups LFB-staining intensities and e Bar chart for the percentage of

myelinated nerve fibres in six random corpus callosum fields/tissue
section. Vertical bars represent the mean ± S.D. of each group. Values are statistically significant at P < 0.05 using one-way ANOVA followed by Tukey–Kramer post hoc tests

neuronal re-myelination via OPCs differentiation induction
(Greenberg and Jin 2006). Dorsomorphin, a pyrazolopyrimidine derivative immensely used as an AMPK inhibitor (Zhou
et al. 2001), was used in the current work to investigate the
involvement of P-AMPK/SIRT1 signaling in Lira-induced
autophagy. Herein, Dorso was not able to abolish the neuroprotective effects of Lira completely, which implies that
the neuroprotective effects of Lira involve not only AMPKdependent but also AMPK-independent mechanisms.
There are several lines of evidence supporting the crucial role of GLP-1R in the growth and vitality of neuronal
cells (Duarte et al. 2013; Hölscher 2014; Yildirim Simsir
et al. 2018; Elbassuoni and Ahmed 2019). Moreover, GLP-1
knock-out mice showed impaired neuronal functions such as
cognition, learning, and memory (Perry et al. 2003; Abbas
et al. 2009). It was reported that GLP-1 has a pivotal effect
in the stimulation of neuronal progenitor cells proliferation
(During et al. 2003), an effect that is beneficial for the restoration of neuronal networks in different CNS diseases such
as Alzheimer’s (Greenberg and Jin 2006; Hansen et al. 2016)
and Parkinson’s diseases (Badawi et al. 2017; Safar et al.
2021). Indeed, the aforementioned data cast light on GLP1R as an emerging potential target of new drug discovery in
the treatment of MS.
Our findings depicted that, Cup was able to induce multiple behavioral and motor dysfunctions as observed in OFT,
rotarod and string testing. These results are explained by

the observed abnormally affected corpus callosum regions,
in parallel to previous findings (Zhen et al. 2017; Zhang
et al. 2020). Whereas, treatment with Lira reversed the
impairments in animals’ behavioral profile in addition to
histopathological abnormalities. Moreover, the findings
were accompanied by a significant Cup-induced decrease
in brain weight, which might be attributed to the reported
ability of Cup to induce neuronal demyelination through the
perturbation of brain mitochondrial metabolic state in mice
(Matsushima and Morell 2001; Liu et al. 2010). Whereas,
treatment with Lira amended Cup-induced reduction in brain
weight, suggesting its potential repurposing in the treatment
of MS. Moreover, Dorso has partially blocked the effect of
Lira on motor and behavioral dysfunctions, as mice received
Dorso showed better behavioral profiles but to a lesser extent
than Lira-treated mice. On the other hand, Dorso failed to
reverse Lira-induced normalized brain weight.
Myelin basic protein, is a main intrinsic component of
the mature compacted myelin sheath covering the neuronal
axons (Stinissen et al. 1998). It is well established as an
indicative biomarker for the assessment of myelination status and re-myelination tendency (García-León et al. 2020).
Herein, Cup administration caused demyelination as manifested by the profound reduction in MBP expression and
hence myelin sheath loss, the major hallmark of MS, which
lends support to previous reports (Clarner et al. 2012; Abd
El Aziz et al. 2021). This finding is affirmed by LFB-staining
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Fig. 5  Effect of Lira on brain p-AMPK/SIRT1 and autophagy biomarkers in Cup-induced demyelination in C57Bl/6 mice. Vertical
bars represent the mean ± S.D. of six mice for a p-AMPK level, b
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SIRT1, c Beclin-1 and d LC3B (II/I) relative protein expression. Values are statistically significant at P < 0.05 using one-way ANOVA followed by Tukey–Kramer post hoc tests
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Fig. 6  Effect of Lira on Cup-induced inflammation and apoptosis via
NLRP3 inflammasome activation in C57Bl/6 mice. Vertical bars represent the mean ± S.D. of six mice for a HMGB1, b & c TLR-4, d

NF-κB, e NLRP3, f caspase-1 and g IL-1β protein expression. Values
are statistically significant at P < 0.05 using one-way ANOVA followed by Tukey–Kramer post hoc tests

of brain corpus callosum showing a reduced percentage of
myelinated nerve fibers. Promisingly, the present study
reveals the potential of Lira to hinder neuronal demyelination and its ability to stimulate re-myelination as Lira-treated
group significantly restored Cup-deranged level of MBP
sections (Carriel et al. 2017). Additionally, Lira treatment
elevated the percentage of myelinated nerve fibers in brain
corpus callosum sections. Furthermore, Dorso abated the
effect of Lira treatment on myelination status as it showed
a lower MBP level than the Lira-treated group, and almost
blocked the protective effect of Lira on myelinated nerve
fibers percent.
In parallel with re-myelination, Olig2, a master transcription factor, is believed to have a pivotal role in OPCs
differentiation into mature myelin-producing OLGs (Szu
et al. 2021). According to our results, Cup ingestion
reduced OPCs re-myelination capacity through lowering Olig2 protein level, which emphasize previous findings (Zhan et al. 2020). However, Lira was able to restore
the OPCs re-myelination ability via Olig2 transcription

activation. On the contrary, administration of Dorso failed
to significantly block the triggering effect of Lira on Olig2
protein expression. This reflects that Lira stimulates Olig2
via other multiple mechanisms. Results of brain weight,
LFB-staining, MBP and Olig2 protein expression suggest
that the mechanism by which Lira reverses Cup-induced
neurotoxicity may be through its potential to induce remyelination and prevent demyelination.
Upon activation of GLP-1R, it stimulates the phosphorylation of AMPK and activates the neuroprotective downstream signaling cascade (Carling et al. 2012). The current
study clearly shows that Lira-treated group exhibited a
significant increase in p-AMPK, which may explain the
significant up-regulatory effect of Lira on SIRT1 suppression triggered by Cup intoxication (Peixoto et al. 2017).
Previous research supports these findings (Elbaz et al.
2018; Houshmand et al. 2019), which revealed that Cup
ingestion induced neurotoxicity via suppressing p-AMPK/
SIRT1 markers. Moreover, Lira-modulatory effect is
affirmed by Dorso co-administration as Lira + Dorso group
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Fig. 7  Effect of Lira on histopathological alterations in Cup-induced
neurotoxicity. Representative images of H&E stained brain corpus
callosum sections of C57Bl/6 mice, (magnification, × 50). a Normal
control group, b Cup-, c Lira- and d Lira + Dorso-treated groups.

Black arrow indicates abnormal glial cells infiltrates, yellow arrow
indicates astroglial and microglial cells infiltrates and red arrow indicates demyelination, vacuolization and axonal damage

Fig. 8  Effect of Lira on Cup-induced microgliosis. Representative
images of anti-Iba-1 Immunohistochemical staining of brain corpus
callosum sections of C57Bl/6 mice (magnification, × 50). a Normal
control group, b Cup-, c Lira-, d Lira + Dorso-treated groups, and e
Box plot chart for the count of active microglial cells that positively

express Iba-1 in six random corpus callosum fields per tissue section.
Vertical bars represent the median and range of each group. ( +) represents the mean. Values are statistically significant at P < 0.05 using
Kruskal–Wallis ANOVA followed by Dunn’s post hoc statistical tests
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showed significantly lower levels of p-AMPK and SIRT1
than Lira-treated group.
In line with its activation effect on AMPK/SIRT1 pathway, Lira markedly enhanced the autophagy machinery as
verified by a significant increment in the autophagy biomarkers Beclin-1 and LC3B levels (Misrielal et al. 2020).
In contrast, Cup was able to diminish the autophagic flux as
shown in the reduced levels of Beclin-1 and LC3B, similar
to what was formerly demonstrated (Dasgupta et al. 2013;
Zhang et al. 2020). Based on the premise that autophagy
activation participate in the regulation of mitochondrial
homeostasis and neuroprotection (Kruppa et al. 2018; Misrielal et al. 2020), our findings depicted the suppressive
effect of Lira on neuroinflammation through abolishing
the Cup-induced mitochondrial damage and cellular debris
via autophagy augmentation. This result is confirmed by
the co-administration of Dorso as it lowered Beclin-1 and
LC3B protein expression. Additionally, this may explain the
significant decrement in HMGB1 level, as one of the most
powerful damage-associated molecular patterns (DAMPs)
(Shi et al. 2018), in Lira-treated group. In this context, we
hypothesized that Lira may indirectly mitigate the activation of TLR-4 and subsequently NLRP3 inflammasomes via
autophagy activation.
It is well established that Cup administration induces
detrimental metabolic oxidative stress and primary OLGs
apoptosis. A state that subsequently increases microglial
activation and microgliosis significantly (Zatta et al. 2005;
Blakemore and Franklin 2008; Hillis et al. 2016). It goes
along with our results, as the Cup-treated group showed
highly expressed Iba-1 in immunohistochemical pictures.
However, Lira was able to mitigate the pathologic microgliosis as it showed a lower Iba-1 level.
The canonical NLRP3 activation is primed by the recognition of several DAMPs by the aid of pattern recognition
receptors such as Toll-like receptors (TLRs) (Yuan et al.
2018). High mobility group box protein-1, a non-histone
DNA-chaperone protein, is a key transcriptional modulator. It is released to the extracellular environment from the
activated macrophages, monocytes, dendritic cells as well
as apoptotic OLGs (Malhotra et al. 2015). Being a powerful DAMP, HMGB1 is detected by the surface TLR-4 and
upregulates the transcription and activation of the inflammatory cytokine NF-κB. Thereafter, triggering NF-κB leads
to the overexpression of inflammasome-related components
such as NLRP3, pro-caspase-1, pro-IL-1β and pro-IL-18 as
well (Agostini et al. 2004; Harris et al. 2011). Following
the priming step, NLRP3 protein forms a heterogeneous
oligomer with apoptosis-associated spec-like protein. Such
oligomer, in turn, catalyzes the proteolysis of pro-caspase-1
into active caspase-1. This further gives rise to the formation and release of mature IL-1β and IL-18 (Ito et al. 2015;
Birnbaum et al. 2018).
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Cuprizone intoxication was able to provoke a heightened
state of inflammation and apoptosis through elevating caspase-1 and IL-1β in brain tissue that is reflected in the histopathological pictures herein (Jha et al. 2010). The observed
significant increase in HMGB1 in the Cup-treated group is
attributed to the activation of immune cells and apoptotic
OLGs, which is consistent with previous findings (Malhotra
et al. 2015). In parallel, this was associated with upregulation of TLR-4 expression (Shi et al. 2018). The activation
of GLP-1 resulted in inhibition of TLR-4 expression by the
tested macrophages (Dai et al. 2014). More importantly, the
current study shows the anti-inflammatory action of Lira via
preventing Cup-induced overexpression of HMGB1 and TLR4, indirectly and directly, respectively. Hence, it promisingly
ameliorates the concomitant increases in NF-κB expression.
These findings are in accordance with the literature data,
which clearly showed that the activation of upregulated TLR-4
by overly expressed HMGB1 is assumed to trigger several cell
responses. It markedly increased NF-κB level (Shi et al. 2018),
as demonstrated in the Cup-treated group in our study. Accordingly, it may elucidate the overexpression of NLRP3, activated
caspase-1 and activated IL-1β, as a downstream cascade, following Cup intoxication.
According to our findings, Lira treatment markedly attenuated the activation and release of the inflammatory cytokines
such as caspase-1 and IL-1β via mitigating the Cup-induced
NLRP3 overexpression. Indeed, IL-1β has been recognized as
a significant contributor to the cellular apoptosis cascade (Cai
et al. 2004; Prins et al. 2013). Therefore, the observed suppressive effect of Lira on IL-1β may contribute to its anti-apoptotic
effect and consequently its anti-inflammatory effect.
Accumulating body of evidence presumed that both
HMGB1/TLR-4 and AMPK/SIRT1 cascades tightly control
NF-κB, which is a crucial transcriptional regulator of neuroinflammation (Liu et al. 2017). Moreover, previous studies
reported the suppressive effect of both SIRT1 on NF-κB (Kuhlmann et al. 2008) and AMPK on TLR-4 expression (Soraya
et al. 2012, 2014). In line with this, the current study depicted
that Lira can mitigate neuroinflammation in Cup-treated mice
through NLRP3 inflammasomes modulation both directly via
GLP-1R and indirectly via AMPK/SIRT1 and autophagy, a
finding that is verified by Dorso administration. Herein, Lira
neuroprotective effect is partially abolished by pre-treatment
with Dorso as it presented a significant decrement in HMGB1,
TLR-4, and NF-κB levels in addition to NLRP3 expression
and its downstream cascade, caspase-1, and IL-1β.

Conclusion
In the current study, Lira exhibited neuroprotective effects
against Cup-induced MS. The findings showed that Lira was
able to restore the impaired behavioral and motor functions
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in Cup-treated mice. In addition, it revealed that Lira could
activate autophagy, curtain inflammation, and suppress
apoptosis. The current study also substantiates the possible
interplay between AMPK/SIRT1, autophagy, and NLRP3
inflammasomes pathways and their role in the potential
anti-inflammatory neuroprotective effect of Lira. At last,
this study offers a new perspective for the use of Lira as a
promising candidate in the management of MS and ameliorating its pathological consequences, especially for diabetic
patients who suffer from multiple sclerosis co-morbidity.
However, further investigations for its beneficial effects on
humans through clinical trials are still needed.
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